Trials / Completed
CompletedNCT06220123
A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
A Multicenter, Randomized, Open-label, Active-controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 225 (actual)
- Sponsor
- Beijing Suncadia Pharmaceuticals Co., Ltd · Industry
- Sex
- Female
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is designed to evaluate the efficacy and safety of SHR-2004 injection in preventing postoperative venous thromboembolism in patients undergoing ovarian cancer surgery.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SHR-2004 | Investigational product arm: SHR-2004 |
| DRUG | Enoxaparin Sodium Injection; Rivaroxaban Tablets | Positive control arm: Enoxaparin Sodium Injection + Rivaroxaban Tablets |
Timeline
- Start date
- 2024-02-16
- Primary completion
- 2024-12-31
- Completion
- 2024-12-31
- First posted
- 2024-01-23
- Last updated
- 2025-07-22
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT06220123. Inclusion in this directory is not an endorsement.